BACKGROUND: Secretoneurin (SN) is a neuropeptide that counterbalances disorders of cell calcium cycling via calmodulin and thus may be involved in arrhythmogenesis. We aimed to associate plasma standard biomarkers and SN levels before, during, and after catheter ablation for atrial fibrillation (AF) with various clinical and paraclinical variables, foremost AF recurrence. METHODS: We prospectively enrolled consecutive patients undergoing catheter ablation for AF in University Hospital Ostrava between March 2023 and January 2024. SN was analyzed from venous, left atrial, and coronary sinus blood with the ELISA method. Plasma SN levels were compared before, during, and after ablation and with those of healthy individuals, with nonparametric tests. ClinicalTrials.gov ID: NCT05794464. RESULTS: A total of 137 patients (64% males, age 63 ± 11) and 34 healthy individuals (38% males, mean age 31 ± 7.1) were included in the analysis. Plasma SN levels were significantly lower after the catheter ablation as compared with SN levels before (34.0 ± 15.1 and 40.0 ± 17.3 pmol/L, p = 0.032). Healthy individuals produced higher plasma SN levels (50.7 ± 15.3 pmol/L) as compared with those in patients with AF both before and after catheter ablation (p = 0.0068, p < 0.001). Furthermore, lower postprocedural levels of SN were associated with AF recurrence (p = 0.035). The C-statistic for SN after the procedure to separate presence or absence of AF recurrence was 0.65 with bootstrap 95% CI 0.5-0.8. Of note, SN after the procedure correlated with plasma NT-proBNP levels (p < 0.001). PFA caused greater myocardial damage than did RFA (p < 0.001); inflammatory markers were increased post procedurally in both the RFA and the PFA group. Subclinical intravascular hemolysis occurred in the PFA group. CONCLUSION: Plasma secretoneurin levels are decreased after catheter ablation for atrial fibrillation; patients with AF produce lower SN levels than healthy individuals. Lower postprocedural levels of SN are associated with AF recurrences.

Department of Internal Medicine and Cardiology University Hospital Ostrava Ostrava Czechia

Institute of Laboratory Medicine University Hospital Ostrava Ostrava Czechia

Institute of Laboratory Medicine University of Ostrava Ostrava Czechia

Research Center for Internal and Cardiovascular Diseases Faculty of Medicine University of Ostrava Syllabova Czechia

Zobrazit více v PubMed

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. (2021) 42(5):373–498. 10.1093/eurheartj/ehaa612 PubMed DOI

Dridi H, Kushnir A, Zalk R, Yuan Q, Melville Z, Marks AR. Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target. Nat Rev Cardiol. (2020) 17(11):732–47. 10.1038/s41569-020-0394-8 PubMed DOI PMC

Heijman J, Voigt N, Nattel S, Dobrev D. Calcium handling and atrial fibrillation. Wien Med Wochenschschr. (2012) 162(13–14):287–91. 10.1007/s10354-012-0109-9 PubMed DOI

Ottesen AH, Louch WE, Carlson CR, Landsverk OJB, Kurola J, Johansen RF, et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J Am Coll Cardiol. (2015) 65(4):339–51. 10.1016/j.jacc.2014.10.065 PubMed DOI

Plášek J, Lazárová M, Dodulík J, Šulc P, Stejskal D, Švagera Z, et al. Secretoneurin as a novel biomarker of cardiovascular episodes: are we there yet? A narrative review. J Clin Med. (2022) 11(23):7191. 10.3390/jcm11237191 PubMed DOI PMC

Ottesen AH, Carlson CR, Eken OS, Sadredini M, Myhre LP, Shen X, et al. Secretoneurin is and endogenous calcium/calmodulin-dependent protein kinase II inhibitor that attenuates Ca2+ - dependent arrhythmia. Circ Arrhythm Electrophysiol. (2019) 12(4):e007045. 10.1161/CIRCEP.118.007045 PubMed DOI

Aakre KM, Ottesen AH, Strand H, Faaren AL, Alaour B, Torsvik J, et al. Biologial variation of secretoneurin;a novel cardiovascular biomarker implicated in arrhythmogenesis. Clin Biochem. (2021) 98:74–7. 10.1016/j.clinbiochem.2021.09.014 PubMed DOI

Plášek J, Dodulík J, Lazárová M, Stejskal D, Švagera Z, Chobolová N. Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results. Front Cardiovasc Med. (2024) 10:1297900. 10.3389/fcvm.2023.1297900 PubMed DOI PMC

Wang Z, Ji WH, Ruan C, LIu XY, Qiu XB, Yuan F, et al. Prevalence and spectrum of TBX5 mutation in patients with lone atrial fibrillation. Int J Med Sci. (2016) 13(1):60–7. 10.7150/ijms.13264 PubMed DOI PMC

Laforest B, Dai W, Tyan L, Lazarevic S, Shen KM, Gadek M, et al. Atrial fibrillation risk loci interact to modulate Ca2+dependent atrial rhythm homeostasis. J Clin Invest. (2019) 129(11):4937–50. 10.1172/JCI124231 PubMed DOI PMC

Liu Z, Finet JE, Wolfram JA, Anderson ME, Ai X, Donahue JK. Calcium/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Heart Rhythm. (2019) 16(7):1080–8. 10.1016/j.hrthm.2019.01.013 PubMed DOI PMC

Yeh YH, Wakili R, Qi XY, Chartier D, Boknik P, Kääb S, et al. Calcium-handling abnormalities underlying atrial arrhythmogenesis and contractile dysfunction in dogs with congestive heart failure. Circ Arrhythm Electrophysiol. (2008) 1(2):93–102. 10.1161/CIRCEP.107.754788 PubMed DOI

Brynildsen J, Petäjä L, Myhre PL, Lyngbaken MN, Nygård S, Stridsberg M, et al. Circulating secretoneurin concentrations after cardiac surgery: data from the Finnish acute kidney injury heart study. Crit Care med. (2019) 47(5):e412–9. 10.1097/CCM.0000000000003670 PubMed DOI

Brynildsen J, Myhre PL, Lynbakken MN, Lyngbaken MN, Klaeboe LG, Stridsberg M, et al. Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis. Clin Biochem. (2019) 71:17–23. 10.1016/j.clinbiochem.2019.06.008 PubMed DOI

Røsjø H, Stridsber M, Ottesen AH, Nygård S, Christensen G, Pettilä V, et al. Prognostic value of secretoneurin in critically ill patients with infections. Crit Care. (2016) 44(10):1882–90. 10.1097/CCM.0000000000001832 PubMed DOI

Aakre KM, Lyngbakken MN, Faaren AL, Røsjø H, Dalen H, Omland T. Reference intervals of circulating secretoneurin concentrations determined in a large cohort of community dwellers: the HUNT study. Clin Chem Lab Med. (2024) 62(10):2030–6. 10.1515/cclm-2024-0154 PubMed DOI

Røsjø H, Meessen J, Ottesen AH, GISSI-HF study investigators. Circulating secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure. Eur Heart J. (2022) 43(suppl2):ehac544.912. 10.1093/eurheartj/ehac544.912 DOI

Myhre P, Ottesen AH, Faaren AL, Tveit SH, Springett J, Pyylampi J. Circulating secretoneurin concentrations are increased in patients with acute coronary syndrome and provide prognostic information. Eur Heart J. (2020) 41(Supplement_2):ehaa946.1368. 10.1093/ehjci/ehaa946.1368 DOI

Liu D, Li Y, Zhao Q. Effects of inflammatory cell death caused by catheter ablation on atrial fibrillation. J Inflamm Res. (2023) 16:3491–508. 10.2147/JIR.S422002 PubMed DOI PMC

Batista Napotnik T, Polajžer T, Miklavčič D. Cell death due to electroporation – A review. Bioelectrochemistry. (2021) 141:107871. 10.1016/j.bioelechem.2021.107871137 PubMed DOI

Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible electroporation: ultrasound and immunohistological correlation. Technol Cancer Res Treat. (2007) 6(4):287–94. 10.1177/153303460700600404138 PubMed DOI

Miyazaki S, Kuroi A, Hachiya H, Nakamura H, Taniguchi H, Ichichara N, et al. Early recurrence after pulmonary vein isolation of paroxysmal atrial fibrillation with different ablation technologies – prospective comparison of radiofrequency vs second-generation cryoballoon ablation. Circ J. (2016) 80(2):346–53. 10.1253/circj.CJ-15-1051 PubMed DOI

Grimaldi M, Di Monaco A, Gomez T, Berman D, Datta K, Sharma T, et al. Time course of irreversible electroporation lesion development through short- and long-term follow-up in pulsed-field ablation-treated hearts. Circ Arrhythm Electrophysiol. (2022) 15(7):e010661. 10.1161/circep.121.010661184 PubMed DOI

Koruth JS, Kuroki K, Kawamura I, Stoffregen WC, Dukkkipati SR, Neužil P, et al. Focal pulsed field ablation for pulmonary vein isolation and linear atrial lesions: a preclinical assessment of safety and durability. Circ Arrhythm Electrophysiol. (2020) 13(6):e008716. 10.1161/circep.120.008716185 PubMed DOI

Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petrů J, Funasako M, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. (2021) 7(5):614–27. 10.1016/j.jacep.2021.02.014 PubMed DOI

Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel Ch, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. (2023) 389(18):1660–71. 10.1056/NEJMoa2307291 PubMed DOI

Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. (2022) 24(8):1256–66. 10.1093/europace/euac050 PubMed DOI PMC

Reddy VY, Ekanem E. Multi-national Survey on the Safety of the Post-approval use of Pulsed Field Ablation in 17000+Patients (MANIFEST-17 K). Presented This at the AHA Late Breaking & Featured Science – Scientific Sessions November 11, 2023. Philadelphia, PA: AHA; (2023).

Venier S, Vaxelaire N, Jacon P, Carabelli A, Desbiolles A, Garban F, et al. Severe acute kidney injury related to haemolysis after pulsed field ablation for atrial fibrillation. Europace. (2023) 26(1):euad371. 10.1093/europace/euad371 PubMed DOI PMC

Tabbara IA. Hemolytic anemias. Diagnosis and management. Med Clin North Am. (1992) 76(3):649–68. 10.1016/S0025-7125(16)30345-5 PubMed DOI

Wassell J. Haptoglobin: function and polymorphism. Clin Lab. (2000) 46(11-12):547–52. PubMed

Tolosano E, Altruda F. Hempexin: structure, function, and regulation. DNA Cell Biol. (2002) 21(4):297–306. 10.1089/104454902753759717 PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05794464